ApoB/ApoA1 ratio and associated factors in older patients with acute coronary syndrome
Main Article Content
Abstract
A cross-sectional study was conducted on 438 patients aged ≥ 60 years old with acute coronary syndrome admitted to An Giang Central General Hospital between January 2024 and January 2026 to characterize the ApoB/ApoA1 ratio and identify associated factors. The median ApoB/ApoA1 ratio was 0.78 (IQR, 0.59 – 0.97). Higher ApoB/ApoA1 ratios were observed in patients with hypertension, diabetes mellitus, dyslipidemia, chronic heart failure, and a history of stroke, and the ratio differed significantly across the three clinical presentations of acute coronary syndrome. In multivariable linear regression with correction for multiple testing, the ApoB/ApoA1 ratio remained independently associated with age (β = -0.058; p-FDR < 0.001), hypertension (β = 0.081; p-FDR = 0.024), chronic heart failure (β = 0.212; p-FDR < 0.001), prior stroke (β = 0.194; p-FDR < 0.001), non-ST-segment elevation myocardial infarction (β = 0.110; p-FDR = 0.024), and hs-CRP (β = 0.098; p-FDR < 0.001). These findings indicate that the ApoB/ApoA1 ratio may provide incremental value as an adjunctive marker of cardiometabolic risk burden in older adults presenting with acute coronary syndrome.
Article Details
Keywords
acute coronary syndrome, older adults, ApoB/ApoA1, characteristics, associated factors
References
2. Jiang Y, He L, Hu D, et al. The ApoB/ApoA-I ratio supersedes conventional lipids in predicting coronary artery disease and clinical phenotypes requiring revascularization. Clin Exp Hypertens. 2026;48(1):2603463. doi: 10.1080/10641963.2025.2603463.
3. Li B, Zhao X, Ding Y, Zhang Y. A potentially underestimated predictor of coronary artery disease risk: The ApoB/ApoA1 ratio. Heliyon. 2024;10(11):e32084. doi: 10.1016/j.heliyon.2024.e32084.
4. Walldius G. High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 1: a review basis for updating guidelines. Expert Rev Cardiovasc Ther. 2025;23(9):521-545. doi: 10.1080/14779072.2025.2543537.
5. Yaseen RI, El-Leboudy MH, El-Deeb HM. The relation between ApoB/ApoA-1 ratio and the severity of coronary artery disease in patients with acute coronary syndrome. Egypt Heart J. 2021;73(1):24. doi: 10.1186/s43044-021-00150-z.
6. Walldius G, de Faire U, Alfredsson L, et al. Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio-Experience from the Swedish AMORIS cohort: A cohort study. PLoS Med. 2021;18(12):e1003853. doi: 10.1371/journal.pmed.1003853.
7. Lâm Hùng Hạnh, Trần Viết An. Giá trị ApoB/ApoA1 và mối liên quan với tổn thương hẹp động mạch vành ở bệnh nhân đau thắt ngực không ổn định. Tạp chí Y học Việt Nam. 2025;551(3):141-145. doi: 10.51298/vmj.v551i3.14718.
8. Phan Thái Hảo, Đinh Đức Huy, Phạm Huy Hoàng. Giá trị của tỷ số apolipoprotein B/apolipoprotein A-I trong dự đoán mức độ tổn thương mạch vành theo thang điểm SYNTAX và kết cục nội viện ở bệnh nhân hội chứng động mạch vành cấp. Tạp chí Y học Việt Nam. 2025;555(1):321-327. doi: 10.51298/vmj.v555i1.15957.
9. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
10. The Third Report of The National Cholesterol Education Program. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
11. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. doi: 10.1093/eurheartj/ehaf190.
12. Ha NM, Lan NTH, Binh PT, et al. Preliminary evidence on the diagnostic value of apolipoprotein B and A-I in peripheral artery disease among Vietnamese patients with diabetes. Tạp chí Nghiên cứu Y học. 2024;184(11E15):62-76. doi: 10.52852/tcncyh.v184i11E15.2537.
13. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224-33. doi: 10.1016/s0140-6736(08)61076-4.
14. Ulloque-Badaracco JR, Al-Kassab-Córdova A, Hernandez-Bustamante EA, et al. Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis. Lipids Health Dis. 2023;22(1):98. doi: 10.1186/s12944-023-01860-w.
15. Deng F, Li D, Lei L, et al. Association between apolipoprotein B/A1 ratio and coronary plaque vulnerability in patients with atherosclerotic cardiovascular disease: an intravascular optical coherence tomography study. Cardiovasc Diabetol. 2021;20(1):188. doi: 10.1186/s12933-021-01381-9.